Study: Psoriasis drug boosts insulin secretion in type 1 diabetes

09/23/2013 |

Type 1 diabetes patients who received the psoriasis medication alefacept attained significant improvements in preserved insulin secretion at four hours compared with those in the placebo group, according to a study in The Lancet Diabetes & Endocrinology. Researchers also found patients in the alefacept arm were using less supplementary insulin and were less likely than those in the control group to experience hypoglycemic episodes one year after starting treatment.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT